TY  - JOUR
AU  - Dang, Chau
AU  - Ewer, Michael S
AU  - Delaloge, Suzette
AU  - Ferrero, Jean-Marc
AU  - Colomer, Ramon
AU  - de la Cruz-Merino, Luis
AU  - Werner, Theresa L
AU  - Dadswell, Katherine
AU  - Verrill, Mark
AU  - Eiger, Daniel
AU  - Sarkar, Sriparna
AU  - de Haas, Sanne Lysbet
AU  - Restuccia, Eleonora
AU  - Swain, Sandra M
PY  - 2022
DO  - 10.3390/cancers14112596
SN  - 2072-6694
UR  - http://hdl.handle.net/10668/20896
T2  - Cancers
AB  - BERENICE (NCT02132949) assessed the cardiac safety of the neoadjuvant−adjuvant pertuzumab−trastuzumab-based therapy for high-risk, HER2-positive early breast cancer (EBC). We describe key secondary objectives at final analysis. Eligible patients...
LA  - en
KW  - cardiac safety
KW  - early breast cancer
KW  - neoadjuvant
KW  - pertuzumab
KW  - trastuzumab
TI  - BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer.
TY  - research article
VL  - 14
ER  -